Movatterモバイル変換


[0]ホーム

URL:


US20140271841A1 - Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin - Google Patents

Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
Download PDF

Info

Publication number
US20140271841A1
US20140271841A1US14/213,553US201414213553AUS2014271841A1US 20140271841 A1US20140271841 A1US 20140271841A1US 201414213553 AUS201414213553 AUS 201414213553AUS 2014271841 A1US2014271841 A1US 2014271841A1
Authority
US
United States
Prior art keywords
meq
epa
dosage unit
statin
capsule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/213,553
Inventor
George Grandolfi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amarin Pharmaceuticals Ireland Ltd
Original Assignee
Amarin Pharmaceuticals Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amarin Pharmaceuticals Ireland LtdfiledCriticalAmarin Pharmaceuticals Ireland Ltd
Priority to US14/213,553priorityCriticalpatent/US20140271841A1/en
Publication of US20140271841A1publicationCriticalpatent/US20140271841A1/en
Assigned to CPPIB CREDIT EUROPE S.À R.L.reassignmentCPPIB CREDIT EUROPE S.À R.L.SECURITY INTEREST (SEE DOCUMENT FOR DETAILS).Assignors: AMARIN PHARMACEUTICALS IRELAND LIMITED
Priority to US16/193,131prioritypatent/US11547710B2/en
Assigned to AMARIN PHARMACEUTICALS IRELAND LIMITEDreassignmentAMARIN PHARMACEUTICALS IRELAND LIMITEDRELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS).Assignors: CPPIB CREDIT EUROPE S.À R.L.
Assigned to AMARIN PHARMACEUTICALS IRELAND LIMITEDreassignmentAMARIN PHARMACEUTICALS IRELAND LIMITEDASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).Assignors: GRANDOLFI, GEORGE
Priority to US18/151,382prioritypatent/US20240016803A1/en
Abandonedlegal-statusCriticalCurrent

Links

Images

Classifications

Definitions

Landscapes

Abstract

The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and a statin and to methods of using the same to treat or prevent cardiovascular-related diseases.

Description

Claims (27)

What is claimed is:
1. A dosage unit comprising:
a capsule shell having a surface layer comprising a statin; and
a fill comprising eicosapentaenoate or a derivative thereof.
2. The dosage unit ofclaim 1, wherein the statin is present in a coating on an exterior surface of the capsule shell.
3. The dosage unit ofclaim 1, wherein the capsule shell comprises gelatin.
4. The dosage unit ofclaim 1, wherein the eicosapentaenoate or a derivative thereof is ethyl eicosapentaenoate.
5. The dosage unit ofclaim 1, wherein the dosage unit comprises at least about 50%, by weight of all fatty acids present, eicosapentaenoate or a derivative thereof.
6. The dosage unit ofclaim 1, wherein the dosage unit comprises no more than about 20%, by weight of all fatty acids present, docosahexaenoate or ester thereof.
7. The dosage unit ofclaim 1, wherein the dosage unit comprises no more than about 5%, by weight of all fatty acids present, of any single fatty acid other than eicosapentaenoate or a derivative thereof.
8. The dosage unit ofclaim 1, wherein the statin is present in an amount of about 1 mg to about 160 mg.
9. The dosage unit ofclaim 1, wherein the eicosapentaenoate or derivative thereof is present in an amount of about 400 mg to about 2400 mg.
10. The dosage unit ofclaim 1, wherein the statin is selected from the group consisting of lovastatin, mevastatin, pitavastatin, rosuvastatin, fluvastatin, atorvastatin, simvastatin, and pravastatin.
11. A dosage unit comprising:
a capsule shell; and
a fill comprising a statin and eicosapentaenoate or a derivative thereof.
12. The dosage unit ofclaim 11, wherein the capsule shell has a surface layer comprising a statin.
13. The dosage unit ofclaim 12, wherein the statin is present in a coating on an exterior surface of the capsule shell.
14. The dosage unit ofclaim 11, wherein the statin is suspended in the eicosapentaenoate or a derivative thereof.
15. The dosage unit ofclaim 14, wherein the statin is in the form of a solid dosage unit.
16. The dosage unit ofclaim 15, wherein the statin is in the form of a tablet.
17. The dosage unit ofclaim 11, wherein the capsule shell comprises gelatin.
18. The dosage unit ofclaim 11, wherein the eicosapentaenoate or a derivative thereof is ethyl eicosapentaenoate.
19. The dosage unit ofclaim 11, wherein the dosage unit comprises at least about 80%, by weight of all fatty acids present, eicosapentaenoate or a derivative thereof.
20. The dosage unit ofclaim 11, wherein the dosage unit comprises no more than about 10%, by weight of all fatty acids present, docosahexaenoate or ester thereof.
21. The dosage unit ofclaim 11, wherein the dosage unit comprises no more than about 5%, by weight of all fatty acids present, of any single fatty acid other than eicosapentaenoate or a derivative thereof.
22. The dosage unit ofclaim 11, wherein the statin is present in an amount of about 1 mg to about 160 mg.
23. The dosage unit ofclaim 11, wherein the eicosapentaenoate or derivative thereof is present in an amount of about 400 mg to about 2400 mg.
24. The dosage unit ofclaim 11, wherein the statin is selected from the group consisting of lovastatin, mevastatin, pitavastatin, rosuvastatin, fluvastatin, atorvastatin, simvastatin, and pravastatin.
25. A method of treating or preventing a cardiovascular-related disease or disorder in a subject, the method comprising administering to the subject a dosage unit comprising a capsule shell having a surface layer comprising a statin and a fill comprising eicosapentaenoate or a derivative thereof.
26. A method of treating or preventing a cardiovascular-related disease or disorder in a subject, the method comprising administering to the subject a dosage unit comprising a capsule shell and a fill comprising a statin and eicosapentaenoate or a derivative thereof.
27. The method ofclaim 26, wherein the capsule shell has a surface layer comprising a statin.
US14/213,5532013-03-152014-03-14Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statinAbandonedUS20140271841A1 (en)

Priority Applications (3)

Application NumberPriority DateFiling DateTitle
US14/213,553US20140271841A1 (en)2013-03-152014-03-14Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US16/193,131US11547710B2 (en)2013-03-152018-11-16Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US18/151,382US20240016803A1 (en)2013-03-152023-01-06Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin

Applications Claiming Priority (2)

Application NumberPriority DateFiling DateTitle
US201361798126P2013-03-152013-03-15
US14/213,553US20140271841A1 (en)2013-03-152014-03-14Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin

Related Child Applications (1)

Application NumberTitlePriority DateFiling Date
US16/193,131ContinuationUS11547710B2 (en)2013-03-152018-11-16Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin

Publications (1)

Publication NumberPublication Date
US20140271841A1true US20140271841A1 (en)2014-09-18

Family

ID=51528064

Family Applications (3)

Application NumberTitlePriority DateFiling Date
US14/213,553AbandonedUS20140271841A1 (en)2013-03-152014-03-14Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US16/193,131ActiveUS11547710B2 (en)2013-03-152018-11-16Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US18/151,382AbandonedUS20240016803A1 (en)2013-03-152023-01-06Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin

Family Applications After (2)

Application NumberTitlePriority DateFiling Date
US16/193,131ActiveUS11547710B2 (en)2013-03-152018-11-16Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US18/151,382AbandonedUS20240016803A1 (en)2013-03-152023-01-06Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin

Country Status (1)

CountryLink
US (3)US20140271841A1 (en)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US9283201B2 (en)2013-03-142016-03-15Amarin Pharmaceuticals Ireland LimitedCompositions and methods for treating or preventing obesity in a subject in need thereof
US9585859B2 (en)2013-10-102017-03-07Amarin Pharmaceuticals Ireland LimitedCompositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US9585856B2 (en)2009-04-292017-03-07Amarin Pharmaceuticals Ireland LimitedStable pharmaceutical composition and methods of using same
US9603826B2 (en)2012-06-292017-03-28Amarin Pharmaceuticals Ireland LimitedMethods of reducing the risk of a cardiovascular event in a subject on statin therapy
US9624492B2 (en)2013-02-132017-04-18Amarin Pharmaceuticals Ireland LimitedCompositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9814733B2 (en)2012-12-312017-11-14A,arin Pharmaceuticals Ireland LimitedCompositions comprising EPA and obeticholic acid and methods of use thereof
US9827219B2 (en)2012-01-062017-11-28Amarin Pharmaceuticals Ireland LimitedCompositions and methods for lowering levels of high-sensitivity C-reactive protein (HS-CRP) in a subject
US9855237B2 (en)2009-04-292018-01-02Amarin Pharmaceuticals Ireland LimitedMethods of treating mixed dyslipidemia
US9855240B2 (en)2013-02-192018-01-02Amarin Pharmaceuticals Ireland LimitedCompositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US10166209B2 (en)2013-02-062019-01-01Amarin Pharmaceuticals Ireland LimitedMethods of reducing apolipoprotein C-III
US10172818B2 (en)2014-06-162019-01-08Amarin Pharmaceuticals Ireland LimitedMethods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10314803B2 (en)2008-09-022019-06-11Amarin Pharmaceuticals Ireland LimitedPharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
EP3412280A4 (en)*2016-02-052019-08-28Korea United Pharm. Inc.Oral composite formulation comprising fat-soluble drug and solid preparation coated with oil repellent base
US10406130B2 (en)2016-03-152019-09-10Amarin Pharmaceuticals Ireland LimitedMethods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10493058B2 (en)2009-09-232019-12-03Amarin Pharmaceuticals Ireland LimitedPharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
US10537544B2 (en)2011-11-072020-01-21Amarin Pharmaceuticals Ireland LimitedMethods of treating hypertriglyceridemia
US10561631B2 (en)2014-06-112020-02-18Amarin Pharmaceuticals Ireland LimitedMethods of reducing RLP-C
US10668042B2 (en)2018-09-242020-06-02Amarin Pharmaceuticals Ireland LimitedMethods of reducing the risk of cardiovascular events in a subject
US10842768B2 (en)2009-06-152020-11-24Amarin Pharmaceuticals Ireland LimitedCompositions and methods for lowering triglycerides
US10888539B2 (en)2013-09-042021-01-12Amarin Pharmaceuticals Ireland LimitedMethods of treating or preventing prostate cancer
US10966968B2 (en)2013-06-062021-04-06Amarin Pharmaceuticals Ireland LimitedCo-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US10966951B2 (en)2017-05-192021-04-06Amarin Pharmaceuticals Ireland LimitedCompositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en)2018-03-022021-07-13Amarin Pharmaceuticals Ireland LimitedCompositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
US11141399B2 (en)2012-12-312021-10-12Amarin Pharmaceuticals Ireland LimitedMethods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US11179362B2 (en)2012-11-062021-11-23Amarin Pharmaceuticals Ireland LimitedCompositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US11291643B2 (en)2011-11-072022-04-05Amarin Pharmaceuticals Ireland LimitedMethods of treating hypertriglyceridemia
US11547710B2 (en)2013-03-152023-01-10Amarin Pharmaceuticals Ireland LimitedPharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US11712428B2 (en)2010-11-292023-08-01Amarin Pharmaceuticals Ireland LimitedLow eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en)2010-11-292023-08-01Amarin Pharmaceuticals Ireland LimitedLow eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11986452B2 (en)2021-04-212024-05-21Amarin Pharmaceuticals Ireland LimitedMethods of reducing the risk of heart failure

Citations (5)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US20070212411A1 (en)*2006-03-092007-09-13Abdel FawzyCoating capsules with active pharmaceutical ingredients
US20080057115A1 (en)*2004-06-112008-03-06Ono Pharmaceutical Co., Ltd.Capsule Stable Against Mastication
US20100278879A1 (en)*2009-04-292010-11-04Amarin Pharma, Inc.Stable pharmaceutical composition and methods of using same
US20110218243A1 (en)*2010-03-042011-09-08Amarin Pharma, Inc.Compositions and methods for treating and/or preventing cardiovascular disease
WO2012128587A2 (en)*2011-03-232012-09-27Hanmi Pharm. Co., Ltd.Oral complex composition comprising omega-3 fatty acid ester and hmg-coa reductase inhibitor

Family Cites Families (341)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US4377526A (en)1981-05-151983-03-22Nippon Suisan Kaisha, Ltd.Method of purifying eicosapentaenoic acid and its esters
US4526902A (en)1983-10-241985-07-02Century Laboratories, Inc.Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions
CA1239587A (en)1983-10-241988-07-26David RubinCombined fatty acid composition for lowering blood cholestrol and triglyceride levels
JPS6135356A (en)1984-07-271986-02-19Nippon Oil & Fats Co LtdAnalyzing method of fatty acid in blood lipid
EP0347509A1 (en)1988-06-211989-12-27Century Laboratories Inc.A process of extraction and purification of polyunsaturated fatty acids from natural sources
US4920098A (en)1986-09-171990-04-24Baxter International Inc.Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases
CA1321767C (en)1986-12-261993-08-31Noriko OkazakiProcess for production of eicosapentaenoic acid
JPS63185390A (en)1987-01-271988-07-30Suntory Ltd Method for producing eicosapentaenoic acid using algae
US5252333A (en)1987-04-271993-10-12Scotia Holdings PlcLithium salt-containing pharmaceutical compositions
US5198468A (en)1987-06-241993-03-30Efamol Holdings PlcEssential fatty acid composition
US4843095A (en)1987-08-071989-06-27Century Laboratories, Inc.Free fatty acids for treatment or propyhlaxis of rheumatoid arthritis arthritis
GB8819110D0 (en)1988-08-111988-09-14Norsk Hydro AsAntihypertensive drug & method for production
US5116871A (en)1988-09-131992-05-26Efamol Holdings PlcFatty acid therapy and compositions for the treatment of myalgic encephalomyelitis
GB2223943A (en)1988-10-211990-04-25Tillotts Pharma AgOral disage forms of omega-3 polyunsaturated acids
US4935243A (en)1988-12-191990-06-19Pharmacaps, Inc.Chewable, edible soft gelatin capsule
JP2839276B2 (en)1989-01-231998-12-16日本分光工業株式会社 Supercritical fluid extraction / separation method and apparatus
GB8906369D0 (en)1989-03-201989-05-04Tisdale Michael JEicosapentaenoic acid
US5457130A (en)1989-03-201995-10-10Cancer Research Campaign Technology LimitedEicosapentaenoic acid used to treat cachexia
DK95490D0 (en)1990-04-181990-04-18Novo Nordisk As PROCEDURE FOR PREPARING TRIGLYCERIDE AND TRIGLYCERIDE COMPOSITION
CA2043615C (en)1990-06-042001-08-14Kazuhiko HataMethod of producing eicosapentaenoic acid or the ester derivative thereof
GB9012651D0 (en)1990-06-061990-07-25Efamol HoldingsEssential fatty acid treatment
JP3103588B2 (en)1990-11-162000-10-30持田製薬株式会社 Lipoprotein (a) lowering agent
SE9101642D0 (en)1991-05-301991-05-30Kabi Pharmacia Ab phospholipids
US5215630A (en)1991-06-041993-06-01Nippon Suisan Kaisha, Ltd.Method of purifying eicosapentaenoic acid or the ester derivative thereof by fractional distillation
WO1993003450A1 (en)1991-07-301993-02-18North Carolina State UniversityMethod and apparatus for measuring blood lipoprotein levels by nmr spectroscopy
DE4133694C2 (en)1991-10-111993-10-07Fresenius Ag Use of an emulsion with polyunsaturated fatty acids for i.v. administration for the treatment of skin diseases
JP3400466B2 (en)1991-10-282003-04-28日本水産株式会社 Method for producing high-purity eicosapentaenoic acid or ester thereof
JPH0649479A (en)1992-07-281994-02-22Maruha CorpStabilization of omega,3-unsaturated fatty acid compound
GB9217780D0 (en)1992-08-211992-10-07Efamol HoldingsFatty acid treatment
US5888541A (en)1992-08-211999-03-30Scotia Holdings PlcFatty acid treatment
JPH0692847A (en)1992-09-111994-04-05Mochida Pharmaceut Co LtdTherapeutic agent for osteoporosis
WO1994010125A1 (en)1992-10-271994-05-11Sandoz Ltd.Glycerin derivatives and uses thereof
GB9300125D0 (en)1993-01-061993-03-03Scotia Holdings PlcCompositions containing esters of unsaturated fatty acids
AU7053494A (en)1993-06-041995-01-03Martek Biosciences CorporationMethod of treating coronary vascular disease using docosahexaenoic acid
GB9318611D0 (en)1993-09-081993-10-27Sandoz Nutrition LtdImprovements in or relating to organic compounds
JP3325995B2 (en)1994-02-282002-09-17ミサワホーム株式会社 Panel joint structure
GB9403857D0 (en)1994-03-011994-04-20Scotia Holdings PlcFatty acid derivatives
GB9404483D0 (en)1994-03-081994-04-20Norsk Hydro AsRefining marine oil compositions
US5385929A (en)1994-05-041995-01-31Warner-Lambert Company[(Hydroxyphenylamino) carbonyl] pyrroles
US5760081A (en)1994-05-101998-06-02The General Hospital CorporationOmega 3 fatty acids in the prevention of ventricular fibrillation
JP3368100B2 (en)1994-06-022003-01-20キヤノン株式会社 Toner for developing electrostatic images
AU711482B2 (en)1994-06-281999-10-14Scotia Holdings PlcCompositions for treatment of diabetic complications
IT1274734B (en)1994-08-251997-07-24Prospa Bv PHARMACEUTICAL COMPOSITIONS CONTAINING POLYUNSATURATED FATTY ACIDS, THEIR ESTERS OR SALTS, WITH VITAMINS OR ANTIOXIDANT PROVITAMINS
US5674488A (en)1994-10-071997-10-07Reich; John J.Method for prevention and treatment of hyperchlolesterolemia by in vivo hydrogenation of cholesterol
JP2780154B2 (en)1995-02-171998-07-30株式会社ヤクルト本社 Yogurt
JPH0840981A (en)1995-03-241996-02-13Nissui Pharm Co LtdEicosapentaenoyl glyceride
MY118354A (en)1995-05-012004-10-30Scarista Ltd1,3-propane diol derivatives as bioactive compounds
GB9509764D0 (en)1995-05-151995-07-05Tillotts Pharma AgTreatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
JPH0959206A (en)1995-08-251997-03-04Nippon Oil & Fats Co LtdProduction of eicosapentaenoic acid and eicosapentaenoic ester
GB9519661D0 (en)1995-09-271995-11-29Scotia Holdings PlcFatty acid treatment
US5763496A (en)1995-11-271998-06-09The Research Foundation Of State University Of New YorkPrevention of atherosclerosis using NADPH oxidase inhibitors
AU2738497A (en)1996-04-241997-11-12Brigham And Women's HospitalOmega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder
US6077828A (en)1996-04-252000-06-20Abbott LaboratoriesMethod for the prevention and treatment of cachexia and anorexia
US6248398B1 (en)1996-05-222001-06-19Applied Materials, Inc.Coater having a controllable pressurized process chamber for semiconductor processing
TW425285B (en)1996-06-102001-03-11Viva America Marketing IncFish oil and garlic nutritive supplement
US5861399A (en)1996-07-171999-01-19Heart Care PartnersMethods and compositions for the rapid and enduring relief of inadequate myocardial function
US20020055539A1 (en)1996-10-022002-05-09Bockow Barry I.Compositions and methods for treating cardiovascular conditions
PL190181B1 (en)1996-10-112005-11-30Scarista LtdPharmaceutic preparation containing eicosapentaenic acid and/or stearidonic acid
JP4176166B2 (en)1996-11-152008-11-05持田製薬株式会社 Treatment for rhabdomyolysis
DK0843972T3 (en)1996-11-202002-12-02Nutricia Nv Food composition containing fats for the treatment of metabolic disorders
US6011049A (en)1997-02-192000-01-04Warner-Lambert CompanyCombinations for diabetes
US20010006644A1 (en)1997-07-312001-07-05David J. BovaCombinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
JPH1180083A (en)1997-09-101999-03-23Nof CorpProduction of eicosapentaenoic ester
US6440961B1 (en)1997-10-272002-08-27Dr. Reddy's Research FoundationTricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
CA2307776C (en)1997-10-302008-01-15Morishita Jintan Co., Ltd.Capsular preparation containing unsaturated fatty acid or derivative thereof and process for producing the same
CA2303864A1 (en)1997-11-251999-06-03Warner-Lambert CompanyInhibition of lipoprotein oxidation
KR100587551B1 (en)1997-12-102006-06-08싸이클로스포린 테라퓨틱스 리미티드 Pharmaceutical Compositions Containing Omega-3 Fatty Acid Oils
NZ500703A (en)1998-11-042001-06-29FPreparation of food-grade marine edible oils by treatment with silica, vacuum steam deodorisation and addition of a herb extract
US20020055529A1 (en)1998-12-022002-05-09Bisgaier Charles LarryMethod for treating alzheimer's disease
GB9901809D0 (en)1999-01-271999-03-17Scarista LimitedHighly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
CA2260397A1 (en)1999-01-292000-07-29Atlantis Marine Inc.Method of converting rendered triglyceride oil from marine sources into bland, stable food oil
US20030104048A1 (en)1999-02-262003-06-05Lipocine, Inc.Pharmaceutical dosage forms for highly hydrophilic materials
US6193999B1 (en)1999-03-012001-02-27Banner Pharmacaps, Inc.Gum acacia substituted soft gelatin capsules
CA2366318A1 (en)1999-03-032000-09-08Ida Royalty ApsNovel pharmaceutical, dietary and cosmetic compositions comprising zinger officinale roscoe, eicosapentaenoic acid and/or docosahexaenoic acid
US6596766B1 (en)1999-03-042003-07-22Suntory LimitedUtilization of material containing docosapentaenoic acid
US20020054871A1 (en)1999-04-122002-05-09Yadong HuangMethods and compositions for use in the treatment of hyperlipidemia
US7112609B2 (en)1999-06-012006-09-26Drugtech CorporationNutritional supplements
US6207699B1 (en)1999-06-182001-03-27Richard Brian RothmanPharmaceutical combinations for treating obesity and food craving
CA2311974A1 (en)1999-06-282000-12-28Nisshin Flour Milling Co., Ltd.Processes of selectively separating and purifying eicosapentaenoic and docosahexaenoic acids or their esters
GB9916536D0 (en)1999-07-141999-09-15Scarista LimitedNutritional or pharmaceutical compositions
ATE394941T1 (en)1999-07-282008-05-15Swiss Caps Rechte & Lizenzen PREPARATION FOR USE AS A MEDICATION AND/OR FOOD SUPPLEMENT
CA2382262C (en)1999-08-302004-12-07Ocean Nutrition Canada Ltd.A nutritional supplement for lowering serum triglyceride and cholesterol levels
US6586438B2 (en)1999-11-032003-07-01Bristol-Myers Squibb Co.Antidiabetic formulation and method
JP4170542B2 (en)1999-11-182008-10-22日油株式会社 Process for producing highly unsaturated fatty acid derivative and high-purity eicosapentaenoic acid derivative
EP1125914A1 (en)2000-02-142001-08-22Nisshin Flour Milling Co., Ltd.Process for separating and purifying eicosapentaenoic acid or its ester
RU2281764C2 (en)2000-03-172006-08-20Адзиномото Ко., Инк.Medicinal agents for treatment of complications associated with diabetes mellitus and neuropathy and their using
EP1157692B1 (en)2000-05-222005-10-05Pro Aparts - Investimentos E Consultoria LdaComposition of fatty acids containing at least 80% by weight of EPA and DHA or their derivatives and its pharmaceutical use
US6620821B2 (en)2000-06-152003-09-16Bristol-Myers Squibb CompanyHMG-CoA reductase inhibitors and method
GB0016045D0 (en)2000-06-292000-08-23Laxdale LimitedTherapeutic combinations of fatty acids
GB0016452D0 (en)2000-07-042000-08-23Kilgowan LimitedVitamin K and essential fatty acids
WO2002011723A1 (en)2000-08-042002-02-14Mason R PrestonSynergistic effect of amlodipine and atorvastatin
JP4391673B2 (en)2000-08-082009-12-24花王株式会社 Oil composition
WO2002013797A2 (en)2000-08-152002-02-21Pfizer Products Inc.Therapeutic combination of a cetp inhibitor and atorvastatin
US6383482B1 (en)2000-08-242002-05-07Vitacost.Com, Inc.Weight loss composition containing green tea, hydroxycitric acid, 5-hydroxytryptophan, glucomannan, picolinate and lactobacillus
GB0101198D0 (en)2001-01-172001-02-28Scherer Technologies Inc R PIngestible compositions containing an odoriferous oil
US7534419B2 (en)2001-01-192009-05-19Depuy Mitek, Inc.Methods of diagnosis and treatment of osteoporosis
ITMI20010129A1 (en)2001-01-252002-07-25Pharmacia & Upjohn Spa ESSENTIAL FATTY ACIDS IN THE THERAPY OF HEART INSUFFICIENCY AND HEART FAILURE
GB0111282D0 (en)2001-05-092001-06-27Laxdale LtdPotentiation of therapeutic effects of fatty acids
PL364093A1 (en)2001-05-302004-12-13Laxdale LimitedCoenzyme q (ubiquinone) and eicosapentaenoic acid (epa)
US20120214771A1 (en)2001-07-272012-08-23Fontini SampalisCompositions for treatment of cardiometabolic disorders
ITMI20012384A1 (en)2001-11-122003-05-12Quatex Nv USE OF POLYUNSATURATED FATTY ACIDS FOR THE PRIMARY PREVENTION OF MAJOR CARDIOVASCULAR EVENTS
EP1450787A4 (en)2001-11-152006-01-25Galileo Pharmaceuticals Inc FORMULATIONS AND METHOD FOR TREATING OR REDUCING INFLAMMABLE STATUS
US20040018248A1 (en)2001-11-292004-01-29Adrianne BendichComposition containing statins and calcium for improved cardiovascular health
ITMI20020269A1 (en)2002-02-122003-08-12Victorix Assets Ltd USE OF OMEGA-3 POLYUNSATURATED ACID ETHYL STERES IN PATIENTS WITH HEART INSUFFICIENCY
JP2003306690A (en)2002-02-182003-10-31Nooburu:Kk Fatty oil composition containing polyunsaturated fatty acid
US20030166614A1 (en)2002-03-012003-09-04Harrison Stanley F.Method for reducing cholesterol and triglycerides
NZ548508A (en)2002-05-032008-04-30Pronova Biocare AsUse of EPA and DHA in preventing cerebral damage wherein the dosage ranges from 0.5 to 5.0g of EPA and/or DHA daily
ES2524000T3 (en)2002-06-052014-12-03Teva Czech Industries S.R.O. Reduction of gelatin crosslinking
CA2390820A1 (en)2002-06-172003-12-17St. Vincent's Hospital Sydney LimitedMethods of diagnosis, prognosis and treatment of cardiovascular disease
US20040001874A1 (en)2002-06-242004-01-01Vital Living, Inc.Safe and effective nutritional supplement formulations and associated regimens adapted to prevent and/or treat targeted diseases or medical or health conditions, and related methods
CA2491445A1 (en)2002-07-022004-01-15Galileo Pharmaceuticals, Inc.Compositions and methods for reduction of inflammatory symptoms and/or biomarkers in female subjects
US20060211761A1 (en)2002-07-082006-09-21Yatendra KumarHmg-coa-reductase inhibitors
US20080200453A1 (en)2002-07-292008-08-21Cincotta Anthony HMethods of treating metabolic syndrome using dopamine receptor agonists
CN1303993C (en)2002-08-202007-03-14日研化学株式会社Soft capsule preparation
US7511131B2 (en)2002-11-132009-03-31Genzyme CorporationAntisense modulation of apolipoprotein B expression
US8017651B2 (en)2002-11-222011-09-13Bionexus, Ltd.Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia
KR20110053281A (en)2002-11-222011-05-19니폰스이산가부시키가이샤 Composition containing an organic substance having a double bond with improved oxidation stability
GB0228079D0 (en)2002-12-022003-01-08Laxdale LtdHuntington's Disease
US8124582B2 (en)2002-12-062012-02-28Fibrogen, Inc.Treatment of diabetes
EP1589930A2 (en)2003-01-082005-11-02Flacco-Nesselroad Family TrustCombination therapy for anticoagulation
GB0301701D0 (en)2003-01-242003-02-26Ensay LtdPsoriasis and Eicosapentaenoic acid
MXPA05008216A (en)2003-01-312005-10-05Procter & GambleMeans for improving the appearance of mammalian keratinous tissue.
JP5362944B2 (en)2003-02-072013-12-11持田製薬株式会社 Prognostic agent for subarachnoid hemorrhage
CA2516333C (en)2003-02-212011-08-23Mochida Pharmaceutical Co., Ltd.Drug for reducing side effects in ribavirin / interferon combination therapy
WO2004078166A2 (en)2003-03-052004-09-16Solvay Pharmaceuticals GmbhUse of omega-3-fatty acids in the treatment of diabetic patients
AU2004222633B2 (en)2003-03-182008-05-01Nestec S.A.Compositions comprising fatty acids and amino acids
US7598227B2 (en)2003-04-162009-10-06Isis Pharmaceuticals Inc.Modulation of apolipoprotein C-III expression
US6846942B2 (en)2003-05-202005-01-25David RubinMethod for preparing pure EPA and pure DHA
US7205329B2 (en)2003-05-302007-04-17Microbia, Inc.Modulators of CRTH2 activity
JP4870430B2 (en)2003-06-202012-02-08持田製薬株式会社 Composition for prevention and treatment of varicose veins
US20050042214A1 (en)2003-07-152005-02-24Gershwin M. EricDiscovery of the microorganism that causes the human autoimmune disease, primary biliary cirrhosis
PT1558220E (en)2003-07-242010-03-12Rasendrakumar JhaOral compositions for treatment of diabetes
US20050132441A1 (en)2003-11-122005-06-16Damude Howard G.Delta15 desaturases suitable for altering levels of polyunsaturated fatty acids in oilseed plants and oleaginous yeast
ITMI20032247A1 (en)2003-11-192005-05-20Tiberio Bruzzese INTERACTION OF POLAR DERIVATIVES OF COMPOUNDS INSATURATED WITH INORGANIC SUBSTRATES
SE0303513D0 (en)2003-12-192003-12-19Pronova Biocare As Use of a fatty acid composition comprising at least one of epa and any or any combination thereof
WO2005063231A2 (en)2003-12-312005-07-14Igennus LimitedFormulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or esther thereof
IL159729A0 (en)2004-01-062004-06-20Doron I FriedmanNon-aqueous composition for oral delivery of insoluble bioactive agents
GB0403247D0 (en)2004-02-132004-03-17Tillotts Pharma AgA pharmaceutical composition
US7022713B2 (en)2004-02-192006-04-04Kowa Co., Ltd.Hyperlipemia therapeutic agent
EP1591114A1 (en)2004-03-122005-11-02Fournier Laboratories Ireland LimitedUse of metformin and orlistat for the treatment or prevention of obesity
US20050215640A1 (en)2004-03-262005-09-29Baxter Jeffrey HHMB compositions and uses thereof
US7923043B2 (en)2004-03-302011-04-12Theta Biomedical Consulting & Development Co., Inc.Method for protecting humans against superficial vasodilator flush syndrome
US20050244367A1 (en)2004-05-032005-11-03Ilypsa, Inc.Phospholipase inhibitors localized in the gastrointestinal lumen
US20050272095A1 (en)2004-05-192005-12-08Ppd Biomarker Discovery Sciences, LlcMethods of identifying biomarkers
GB0413729D0 (en)2004-06-182004-07-21Tillotts Pharma AgA pharmaceutical composition and its use
GB0413730D0 (en)2004-06-182004-07-21Tillotts Pharma AgA pharmaceutical composition and its use
JP2007284350A (en)2004-07-272007-11-01Takeda Chem Ind LtdTherapeutic agent for diabetes
ITRM20040395A1 (en)2004-08-032004-11-03Sigma Tau Ind Farmaceuti COMPOSITION INCLUDING STATINES AND FATTY ACIDS OMEGA 3.
WO2006017627A2 (en)2004-08-062006-02-16Barry SearsDietary compositions comprising docosahexaenoic acid and eicosapentaenoic acid and use thereof for treating insulin resistance
EP1786414A4 (en)2004-08-062008-04-09Transform Pharmaceuticals IncNovel statin pharmaceutical compositions and related methods of treatment
US20090042979A1 (en)2004-08-062009-02-12Transform Pharmaceuticals Inc.Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
EP1782807B1 (en)2004-08-182017-08-09Mochida Pharmaceutical Co., Ltd.Jelly composition
AU2005280058B2 (en)2004-08-252010-09-02Essentialis, Inc.Pharmaceutical formulations of potassium ATP channel openers and uses thereof
US20070265353A1 (en)2004-08-272007-11-15Senju Pharmaceutical Co., Ltd.Eye Drops for the Treatment of Dry Eye
CN1759834B (en)2004-09-172010-06-23中国医学科学院医药生物技术研究所Application of berberine or associated with Simvastatin in preparing product for preventing or curing disease or symptom related to blood fat
CA2581816A1 (en)2004-09-272006-04-06Sigmoid Biotechnologies LimitedMicrocapsules comprising a methylxanthine and a corticosteroid
WO2006085144A2 (en)2004-10-152006-08-17Photonz Corporation LimitedCompositions containing high omega-3 and low saturated fatty acid levels
FR2878747B1 (en)2004-12-032007-03-30Pierre Fabre Medicament Sa USE OF OMEGA-3 FATTY ACID (S) FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA CAUSED BY ANTI-RETROVIRAL TREATMENT IN HIV INFECTED PATIENTS
US20070191467A1 (en)2004-12-062007-08-16Reliant Pharmaceutical, Inc.Statin and omega-3 fatty acids for lipid therapy
US20090239927A1 (en)2004-12-062009-09-24George BobotasStatin and Omega-3 Fatty Acids For Lipid Therapy
US20060211762A1 (en)2004-12-062006-09-21Rongen Roelof MOmega-3 fatty acids and dyslipidemic agent for lipid therapy
CN101098690A (en)2004-12-062008-01-02瑞莱恩特医药品有限公司Omega-3 fatty acids and dyslipidemic agent for lipid therapy
US20060135610A1 (en)2004-12-222006-06-22Bortz Jonathan DCardiovascular compositions
GB2421909A (en)2004-12-232006-07-12Laxdale LtdPharmaceutical compositions comprising EPA and methods of use
CA2593768C (en)2005-01-042014-02-18Mochida Pharmaceutical Co., Ltd.Use of .omega.3 unsaturated fatty acids for relieving lipotoxicity
US20080200707A1 (en)2005-01-042008-08-21Mochida-Pharmaceuticals Pharmaceutical Co., Ltd.Lipotoxicity Relieving Agent
NZ560481A (en)2005-01-102010-02-26Cortendo Invest AbMethods and compositions for treating diabetes, metabolic syndrome and other conditions
US20060172012A1 (en)2005-01-282006-08-03Finley John WAnti-inflammatory supplement compositions and regimens to reduce cardiovascular disease risks
US20060189682A1 (en)2005-02-022006-08-24Payne Joseph EWater soluble prodrugs of COX-2 inhibitors
CN101189011A (en)2005-02-172008-05-28默克公司 Methods of treating atherosclerosis, lipid abnormalities, and related conditions
US20100254951A1 (en)2005-02-222010-10-07Mochida Pharmaceutical Co., Ltd.Nerve Regeneration Promoting Agent
WO2006096806A2 (en)2005-03-082006-09-14Reliant Pharmaceutiacals, Inc.Treatment with statin and omega-3 fatty acids and a combination product thereof
AU2006242914B2 (en)2005-05-042012-02-02Pronova Biopharma Norge AsNew DHA derivatives and their use as medicaments
EP1790339B1 (en)2005-07-082014-06-04Mochida Pharmaceutical Co., Ltd.Composition for prevention of occurrence of cardiovascular event
CA2615944A1 (en)2005-07-182007-01-25Reliant Pharmaceuticals, Inc.Treatment with azetidinone-based cholesterol absorption inhibitors and omega-3 fatty acids and a combination product thereof
RU2290185C1 (en)2005-07-262006-12-27Дмитрий Николаевич МясниковComposition for normalization of lipid metabolism and reducing body mass and method for its preparing
WO2007016256A2 (en)2005-07-282007-02-08Reliant Pharmaceuticals, Inc.Treatment with dihydropyridine calcium channel blockers and omega-3 fatty acids and a combination product thereof
ITMI20051560A1 (en)2005-08-102007-02-11Tiberio Bruzzese COMPOSITION OF N-3 FATTY ACIDS WITH HIGH CONCENTRATION OF EPA AND E-O DHA AND CONTAINING N-6 FATTY ACIDS
RU2302248C2 (en)2005-08-302007-07-10Федеральное государственное унитарное предприятие Тихоокеанский научно-исследовательский рыбохозяйственный центрPreparation being of lipid-correcting, hypocoagulative and antioxidant properties
US7405302B2 (en)2005-10-112008-07-29Amira Pharmaceuticals, Inc.5-lipoxygenase-activating protein (FLAP) inhibitors
US20090227602A1 (en)2005-10-282009-09-10John GriffinCompositions and treatments for inhibiting kinase and/or hmg-coa reductase
US20070105793A1 (en)2005-11-042007-05-10Curt HendrixCompositions and methods using nicotinic acid for treatment of hypercholesterolemia, hyperlipidemia nd cardiovascular disease
US20070104779A1 (en)2005-11-072007-05-10Rongen Roelof MTreatment with omega-3 fatty acids and products thereof
CA2628305C (en)2005-11-112014-05-06Mochida Pharmaceutical Co., Ltd.Jelly composition
WO2007058523A1 (en)2005-11-172007-05-24N.V. NutriciaComposition with docosapentaenoic acid
JP2009516681A (en)2005-11-212009-04-23テバ ファーマシューティカル インダストリーズ リミティド Atorvastatin formulation
JP2009520824A (en)2005-12-202009-05-28セネストラ エルエルシー Omega 3 fatty acid preparation
EP1800675B1 (en)2005-12-232011-05-18N.V. NutriciaComposition comprising polyunsaturated fatty acids, proteins, manganese and/or molybden and nucleosides/nucleotides for treating dementia
WO2007081773A2 (en)2006-01-052007-07-19Reliant Pharmaceuticals, IncTreatment of fatty liver
EP1905424A3 (en)2006-02-022008-04-30Ranbaxy Laboratories LimitedProcess for the preparation of a pharmaceutical composition comprising stabilized statin particles
EP2526937A1 (en)2006-02-072012-11-28Mochida Pharmaceutical Co., Ltd.Composition for prevention of recurrence of stroke
BRPI0707794A2 (en)2006-02-142011-05-10Intercept Pharmaceuticals Inc bile acid derivatives, formulations and pharmaceutical compositions, as well as use of said compounds
JP5628480B2 (en)2006-03-092014-11-19グラクソスミスクライン エルエルシー Coated capsule containing pharmaceutical ingredients
WO2007128801A1 (en)2006-05-082007-11-15Novartis AgCombination of organic compounds
EP2022495B1 (en)2006-05-312014-07-23Mochida Pharmaceutical Co., Ltd.Composition for preventing the occurrence of cardiovascular event in multiple risk patient
US20070292501A1 (en)2006-06-052007-12-20Udell Ronald GChewable soft gelatin capsules
EP2044208A4 (en)2006-07-052012-02-22Photonz Corp LtdProduction of ultrapure epa and polar lipids from largely heterotrophic culture
WO2008012329A2 (en)2006-07-282008-01-31V. Mane FilsSeamless capsules containing high amounts of polyunsaturated fatty acids and a flavouring component
US20080085911A1 (en)2006-10-102008-04-10Reliant Pharmaceuticals, Inc.Statin and omega-3 fatty acids for reduction of apo-b levels
CN101553221A (en)2006-10-102009-10-07瑞莱恩特医药品有限公司Statin and omega-3 fatty acids for reduction of APO-B levels
JP2010506920A (en)2006-10-182010-03-04リライアント・ファーマシューティカルズ・インコーポレイテッド Omega-3 fatty acids for reducing LP-PLA2 concentration
US20080125490A1 (en)2006-11-032008-05-29My SvenssonTreatment and prevention of cardiovascular disease in patients with chronic kidney disease by administering Omega-3 Fatty Acids
US20080306154A1 (en)2006-11-032008-12-11My SvenssonTreatment and prevention of major adverse cardiovascular events or major coronary evens by administering Omega-3 fatty acids
ES2524320T3 (en)2007-01-172014-12-05Mochida Pharmaceutical Co., Ltd. Composition for the prevention or treatment of disease associated with thrombus or embolus
US8008328B2 (en)2007-01-232011-08-30Reddy Us Therapeutics, Inc.Methods for the treatment of diabetes-associated dyslipdemia
US20080185198A1 (en)2007-02-022008-08-07Steven Mark JonesNext generation hybrid III parallel/series hybrid system
EP2121576B1 (en)2007-02-152015-11-11Centre De Recherche Sur Les Biotechnologies MarinePolyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
CA2677036A1 (en)2007-03-062008-09-12Bioriginal Food & Science Corp.Soft gelatin capsule shells containing oil soluble flavoring and methods of making the same
WO2008115529A1 (en)2007-03-202008-09-25Reliant Pharmaceuticals, Inc.Compositions comprising omega-3 fatty acids and cetp inhibitors
WO2008145170A1 (en)2007-05-312008-12-04Siemens AktiengesellschaftMethod for configuring an automation system
US20080299187A1 (en)2007-06-012008-12-04Joar OpheimSubstances for Reducing Occurence of Major Cardiac Events in Humans
CN101801416B (en)2007-06-292012-10-24武田药品工业株式会社Sealmess capsule
US8969400B2 (en)2007-10-012015-03-03Duke UniversityPharmaceutical compositions of 5-hydroxytryptophan and serotonin-enhancing compound
US8361534B2 (en)2007-12-202013-01-29Abbott LaboratoriesStable nutritional powder
NZ585619A (en)2007-12-202012-06-29Abbott LabNutritional powder composition comprising carbohydrate, lipid, hydrolysed whey and intact protein
NZ600720A (en)*2008-01-102012-12-21Takeda PharmaceuticalA Seamless Capsule For A Liquid Pharmaceutical Composition
US20090182049A1 (en)2008-01-162009-07-16Joar Arild OpheimPharmaceutical Composition and Method for Treating Hypertriglyceridemia and Hypercholesterolemia in Humans
CA2724463C (en)2008-05-152017-10-03Pronova Biopharma Norge AsKrill oil process
CA2724983A1 (en)2008-05-202009-11-26Mochida Pharmaceutical Co., Ltd.Composition for preventing cardiovascular event in high-risk patient
JPWO2009151125A1 (en)2008-06-132011-11-17持田製薬株式会社 Diagnosis and treatment of liver damage
WO2009151116A1 (en)2008-06-132009-12-17持田製薬株式会社Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis
US20110105510A1 (en)2008-06-172011-05-05Hiroshi IshikawaProphylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis
JP5922868B2 (en)2008-07-072016-05-24持田製薬株式会社 Drugs for improving or treating dyslipidemia
DK2334295T3 (en)2008-09-022017-10-09Amarin Pharmaceuticals Ie Ltd PHARMACEUTICAL COMPOSITION COMPREHENSIVE EICOSAPENTAIC ACID AND NICOTIC ACID AND PROCEDURES FOR USING SAME
WO2010038796A1 (en)2008-09-302010-04-08持田製薬株式会社Therapeutic agent for hepatitis c
US20100130608A1 (en)2008-10-012010-05-27Martek Biosciences CorporationCompositions and methods for reducing triglyceride levels
WO2010080976A1 (en)2009-01-092010-07-15Sdg, Inc. (An Ohio Corporation)Insulin therapies for the treatment of diabetes, diabetes related ailments, and/or diseases or conditions other than diabetes or diabetes related ailments
US9023820B2 (en)2009-01-262015-05-05Protiva Biotherapeutics, Inc.Compositions and methods for silencing apolipoprotein C-III expression
KR20140007973A (en)2009-02-102014-01-20아마린 파마, 인크.Methods of treating hypertriglyceridemia
CA3065860A1 (en)2009-03-092010-09-16Pronova Biopharma Norge AsCompositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof
US8241672B2 (en)2009-03-112012-08-14Stable Solutions LlcOmega-3 enriched fish oil-in-water parenteral nutrition emulsions
WO2010117951A1 (en)2009-04-062010-10-14The Regents Of The University Of CaliforniaInhibitors of soluble epoxide hydrolase to inhibit or prevent niacin-induced flushing
CN104042617A (en)2009-04-292014-09-17阿马里纳药物爱尔兰有限公司Pharmaceutical Compositions Comprising Epa And A Cardiovascular Agent And Methods Of Using The Same
CA2972063C (en)2009-05-222019-12-17Mochida Pharmaceutical Co., Ltd.Self-emulsifying composition of .omega.3 fatty acid
HUE054298T2 (en)2009-06-152021-08-30Amarin Pharmaceuticals Ie Ltd Compositions and methods for treating stroke in a subject on concomitant statin therapy
RU2402326C1 (en)2009-06-222010-10-27Учреждение Российской академии медицинских наук Дальневосточный научный центр физиологии и патологии дыхания Сибирского отделения Российской академии медицинских наук (ДНЦ ФПД СО РАМН)Method for insulin resistance correction in metabolic syndrome
US8557275B2 (en)2009-07-232013-10-15U.S. Nutraceuticals, LLCComposition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA
RU2569063C2 (en)2009-09-012015-11-20Катабэйсис Фармасьютикалз, Инк.Conjugates of fatty acids and niacin and application thereof
WO2011038122A1 (en)2009-09-232011-03-31Amarin Corporation PlcPharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
US9717703B2 (en)2009-10-162017-08-01Glaxosmithkline LlcEmulsion and emulsion preconcentrate compositions comprising omega-3 fatty acids and uses thereof are disclosed
WO2011046204A1 (en)2009-10-162011-04-21持田製薬株式会社Marker associated with non-alcoholic steatohepatitis
ES2637266T3 (en)2010-01-082017-10-11Catabasis Pharmaceuticals, Inc. Fatty acid fumarate derivatives and their uses
US20110178105A1 (en)2010-01-152011-07-21E.I. Du Pont De Nemours And CompanyClinical benefits of eicosapentaenoic acid in humans
US8846321B2 (en)2010-03-122014-09-30President And Fellows Of Harvard CollegeAssociation of levels of HDL-cholesterol apolipoprotein CIII with the risk of coronary heart disease and cardiovascular events
US8663704B2 (en)2010-04-302014-03-04U.S. Nutraceuticals, LLCComposition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (LDL) per-oxidation in humans
AU2011249630B2 (en)2010-05-052014-01-23St. Giles Foods LimitedEdible compositions and methods of manufacturing edible compositions
US8609138B2 (en)*2010-06-302013-12-17Mochida Pharmaceutical Co., Ltd.ω3 fatty acid compound preparation
AR082930A1 (en)2010-09-082013-01-16Pronova Biopharma Norge As COMPOSITIONS THAT INCLUDE AN OILY MIXTURE OF FATTY ACIDS, A TENSIOACTIVE AND A STATIN
US10557856B2 (en)2010-09-242020-02-11University Of Pittsburgh-Of The Commonwealth System Of Higher EducationBiomarkers of renal injury
US20130260403A1 (en)2010-10-202013-10-03GlycoMark Inc.Identification of pre-diabetes using a combination of mean glucose and 1,5-anhydroglucitol markers
US20130303614A1 (en)2010-11-092013-11-14Nippon Suisan Kaisha, Ltd.Agent for inhibiting elevation in blood glucose level
EP2646013A4 (en)2010-11-292014-03-26Amarin Pharma IncLow eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en)2010-11-292023-08-01Amarin Pharmaceuticals Ireland LimitedLow eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
EP2471537A1 (en)2010-12-302012-07-04PregLem S.A.Treatment of pain associated with dislocation of basal endometrium
EP2502506A1 (en)2011-03-212012-09-26Abbott LaboratoriesMethods for improving bone health in infants using long chain polyunsaturated fatty acids
US20120264824A1 (en)2011-04-152012-10-18Mochida Pharmaceutical Co., Ltd.Compositions and methods for treating non-alcoholic steatohepatitis
US8660662B2 (en)2011-04-222014-02-25Medtronic, Inc.Low impedance, low modulus wire configurations for a medical device
ES2833468T3 (en)2011-04-272021-06-15Ionis Pharmaceuticals Inc Modulation of Apolipoprotein CIII (APOCIII) Expression
JP2014531444A (en)2011-09-152014-11-27オムセラ・ファーマシューティカルズ・インコーポレイテッド Methods and compositions for treating, reversing, inhibiting or preventing resistance to antiplatelet therapy
US11291643B2 (en)2011-11-072022-04-05Amarin Pharmaceuticals Ireland LimitedMethods of treating hypertriglyceridemia
US20130131170A1 (en)2011-11-072013-05-23Amarin Pharmaceuticals Ireland LimitedMethods of treating hypertriglyceridemia
EP2792746A4 (en)2011-12-122015-09-16Nat Cerebral & Cardiovascular Ct ANISI OLIGONUCLEOTIDE AS A THERAPEUTIC AGENT FOR HYPERLIPIDEMIA CONTAINING THIS OLIGONUCLEOTIDE AS ACTIVE INGREDIENT
WO2013103958A1 (en)2012-01-062013-07-11Amarin Pharmaceuticals Ireland LimitedCompositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
WO2013136277A1 (en)2012-03-132013-09-19Unimark Remedies Ltd.Pharmaceutical compositions for treatment of cardiovascular diseases
IL249821B (en)2012-03-302019-04-30Sancilio & Company IncOmega-3 fatty acid ester compositions
US20130295173A1 (en)2012-05-072013-11-07Omthera Pharmaceuticals, Inc.Compositions of statins and omega-3 fatty acids
WO2013172344A1 (en)2012-05-152013-11-21持田製薬株式会社Cardiovascular disease primary prevention agent for patients having high blood levels of high-sensitivity c-reactive protein
CN104540551A (en)2012-05-302015-04-22科莱恩金融(Bvi)有限公司Composition containing amino acid surfactants, betaines and N-methyl-N-acylglucamines and having improved foam quality and higher viscosity
US20130324607A1 (en)2012-06-052013-12-05Amarin Pharmaceuticals Ireland LimitedMethods of treating hypercholesterolemia
US20140080850A1 (en)2012-06-052014-03-20Amarin Pharmaceuticals Ireland LimitedPharmaceutical composition comprising an omega-3 fatty acid and a hydroxy-derivative of a statin and methods of using same
HK1209021A1 (en)2012-06-072016-03-24President And Fellows Of Harvard CollegeNanotherapeutics for drug targeting
CA2916208A1 (en)2012-06-172013-12-27Matinas Biopharma, Inc.Omega-3 pentaenoic acid compositions and methods of use
US20140005265A1 (en)2012-06-292014-01-02Amarin Pharmaceuticals Ireland LimitedMethods for treating hypertriglyceridemia
SG10201913647QA (en)2012-06-292020-03-30Amarin Pharmaceuticals Ie LtdMethods of reducing the risk of a cardiovascular event in a subject on statin therapy
US20150157593A1 (en)2012-06-292015-06-11Amarin Pharmaceuticals Ireland LimitedMethods of reducing ldl-p
EP3682875A3 (en)2012-06-292020-10-21Amarin Pharmaceuticals Ireland LimitedMethods of treating pediatric metabolic syndrome
US20140004183A1 (en)2012-06-292014-01-02Amarin Pharmaceuticals Ireland LimitedMethods for treating cardiovascular disease in statin-tolerant subjects
JP6196225B2 (en)2012-09-282017-09-13持田製薬株式会社 Composition for reducing the onset of new diabetes
WO2014057522A1 (en)2012-10-122014-04-17Mochida Pharmaceutical Co., Ltd.Compositions and methods for treating non-alcoholic steatohepatitis
EP2719382A1 (en)2012-10-122014-04-16Mochida Pharmaceutical Co., Ltd.Ethyl Eicosapentanoate and Pharmaceutical Compositions Comprising Ethyl Eicosapentanoate as an Active Ingredient for Use in the Treatment of Non-Alcoholic Steatohepatitis
US20140142127A1 (en)*2012-10-232014-05-22Almburg, LlcStable Compositions of HMG-COA Reductase Inhibitors and Omega-3 Oils
US20150265566A1 (en)2012-11-062015-09-24Amarin Pharmaceuticals Ireland LimitedCompositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US20140213648A1 (en)2012-12-312014-07-31Amarin Pharmaceuticals Ireland LimitedMethods of increasing epa blood levels
US9814733B2 (en)2012-12-312017-11-14A,arin Pharmaceuticals Ireland LimitedCompositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en)2012-12-312014-07-03Amarin Pharmaceuticals Ireland LimitedMethods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US20140221676A1 (en)2013-02-062014-08-07Amarin Pharmaceuticals Ireland LimitedCompositions and methods for treating and/or preventing cardiovascular disease
US9452151B2 (en)2013-02-062016-09-27Amarin Pharmaceuticals Ireland LimitedMethods of reducing apolipoprotein C-III
US20140221452A1 (en)2013-02-062014-08-07Amarin Pharmaceuticals Ireland LimitedCompositions comprising eicosapentaenoic acid and 5-htp and methods of use thereof
US20140221358A1 (en)2013-02-062014-08-07Amarin Pharmaceuticals Ireland LimitedCompositions comprising eicosapentaenoic acid and diazoxide and methods of use thereof
US9624492B2 (en)2013-02-132017-04-18Amarin Pharmaceuticals Ireland LimitedCompositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en)2013-02-192017-05-30The Regents Of The University Of ColoradoCompositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US20140242216A1 (en)2013-02-242014-08-28Mead Johnson Nutrition CompanyAmino Acid And Protein Hydrolysate Based Formulas With A Stable Emulsion System
US20140249225A1 (en)2013-03-012014-09-04Amarin Pharmaceuticals Ireland LimitedMethods of reducing or preventing oxidative modification of membrane polyunsaturated fatty acids
US20140249220A1 (en)2013-03-012014-09-04Amarin Pharmaceuticals Ireland LimitedCompositions and methods for reducing a fatty acid desaturation index in a subject in need thereof
US20140249214A1 (en)2013-03-012014-09-04Amarin Pharmaceuticals Ireland LimitedCo-administration of warfarin and ethyl eicosapentaenoate
US20140249200A1 (en)2013-03-012014-09-04Amarin Pharmaceuticals Ireland LimitedCo-administration of atorvastatin and ethyl eicosapentaenoic acid or a derivative thereof
US9661874B2 (en)2013-03-112017-05-30Mead Johnson Nutrition CompanyNutritional compositions containing structured fat globules and uses thereof
US20140255537A1 (en)2013-03-112014-09-11Mead Johnson Nutrition CompanyNutritional Compositions Containing an Enriched Lipid Fraction and Uses Thereof
US9283201B2 (en)2013-03-142016-03-15Amarin Pharmaceuticals Ireland LimitedCompositions and methods for treating or preventing obesity in a subject in need thereof
US20140271907A1 (en)2013-03-142014-09-18Amarin Pharmaceuticals Ireland LimitedCompositions comprising eicosapentaenoic acid and krill oil and methods of use thereof
US20140275252A1 (en)2013-03-142014-09-18Amarin Pharmaceuticals Ireland LimitedMethods of treating traumatic brain injury
US10441560B2 (en)2013-03-152019-10-15Mochida Pharmaceutical Co., Ltd.Compositions and methods for treating non-alcoholic steatohepatitis
US20140271841A1 (en)2013-03-152014-09-18Amarin Pharmaceuticals Ireland LimitedPharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US9889108B2 (en)2013-03-152018-02-13Mochida Pharmaceutical Co., Ltd.Compositions and methods for treating non-alcoholic steatohepatitis
US20140322314A1 (en)2013-04-292014-10-30Matinas Biopharma, Inc.Omega-3 Fatty Acid Formulations for Use as Pharmaceutical Treatment
KR102240429B1 (en)*2013-05-062021-04-15한미약품 주식회사Composite formulation comprising a film coating layer containing rosuvastatin or a pharmaceutically acceptable salt thereof
US20140357717A1 (en)2013-06-042014-12-04Amarin Pharmaceuticals Ireland LimitedMethods of treating hypertriglyceridemia
US10966968B2 (en)2013-06-062021-04-06Amarin Pharmaceuticals Ireland LimitedCo-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
CN105392364B (en)2013-06-072018-09-14加州生物医学研究所The micromolecular inhibitor of fibrosis
US20160135702A1 (en)2013-06-212016-05-19The Board Of Trustees Of The Leland Stanford Junior UniversityTechniques for Predicting Cardiac Arrhythmias Based on Signals from Leads of Electrocardiography
EP3735963B1 (en)2013-07-182023-09-13Mochida Pharmaceutical Co., Ltd.Self-emulsifying composition of omega-3 fatty acid
ES2841344T3 (en)2013-07-182021-07-08Mochida Pharm Co Ltd Self-emulsifying composition of omega-3 fatty acids
US20150045431A1 (en)2013-08-062015-02-12Amarin Pharmaceuticals Ireland LimitedMethods of treating a cardiovascular disorder in a subject on apo-c3 modulating therapy
US20150051282A1 (en)2013-08-142015-02-19Amarin Pharmaceuticals Ireland LimitedMethods of treating a cardiovascular disorder and/or joint pain in a subject on glucosamine therapy
US20150065572A1 (en)2013-09-042015-03-05Amarin Pharmaceuticals Ireland LimitedMethods of treating or preventing prostate cancer
US20150073050A1 (en)2013-09-092015-03-12Amarin Pharmaceuticals Ireland LimitedCo-administration of omeprazole and eicosapentaenoic acid or a derivative thereof
WO2015053379A1 (en)2013-10-072015-04-16Mochida Pharmaceutical Co., Ltd.Compositions and methods for treating non-alcoholic steatohepatitis
US9585859B2 (en)2013-10-102017-03-07Amarin Pharmaceuticals Ireland LimitedCompositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
WO2015066512A1 (en)2013-10-312015-05-07Amarin Pharmaceuticals Ireland LimitedMethods of treating hypertriglyceridemia
BR112016023269A8 (en)2014-04-112021-06-29Cymabay Therapeutics Inc use of (r)-2-(4-((2-ethoxy-3-(4-(trifluoromethyl)phenoxy)propyl)-thio)-2-methylphenoxy)-acetic acid or salt thereof in the manufacture of a medicine for treat non-alcoholic fatty liver disease or non-alcoholic steatohepatitis
US10561631B2 (en)2014-06-112020-02-18Amarin Pharmaceuticals Ireland LimitedMethods of reducing RLP-C
WO2015195662A1 (en)2014-06-162015-12-23Amarin Pharmaceuticals Ireland LimitedMethods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
EP3248599B1 (en)2015-01-212022-07-06Mochida Pharmaceutical Co., Ltd.Omega-3 fatty acid self-emulsifying composition
WO2016117057A1 (en)2015-01-212016-07-28持田製薬株式会社SELF-EMULSIFYING COMPOSITION OF ω-3 FATTY ACID
WO2016140949A1 (en)2015-03-022016-09-09Amarin Pharmaceuticals Ireland LimitedMethods of reducing or preventing oxidative modification of membrane polyunsaturated fatty acids
US20170151202A1 (en)2015-09-092017-06-01Amarin Pharmaceuticals Ireland LimitedMethods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US10406130B2 (en)2016-03-152019-09-10Amarin Pharmaceuticals Ireland LimitedMethods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
HUE053081T2 (en)2016-07-292021-06-28Kowa Co Methods for the prevention of cardiovascular events in residual dyslipidemic populations
US11197870B2 (en)2016-11-102021-12-14Galmed Research And Development LtdTreatment for hepatic fibrosis
TW201900160A (en)2017-05-192019-01-01愛爾蘭商艾瑪琳製藥愛爾蘭有限公司Compositions and Methods for Lowering Triglycerides in a Subject Having Reduced Kidney Function
US20190054054A1 (en)2017-08-152019-02-21Amarin Pharmaceuticals Ireland LimitedMethods reducing or preventing oxidation of high density lipoprotein (HDL)
US20190054058A1 (en)2017-08-152019-02-21Amarin Pharmaceuticals Ireland LimitedMethods of Treating or Preventing Bone Loss
US20190209506A1 (en)2018-01-092019-07-11Amarin Pharmaceuticals Ireland LimitedMethods of reducing or preventing oxidation of ldl or lipid membranes in a subject in need thereof
US11058661B2 (en)2018-03-022021-07-13Amarin Pharmaceuticals Ireland LimitedCompositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
US20190275057A1 (en)2018-03-062019-09-12Amarin Pharmaceuticals Ireland LimitedCompositions and Methods for Lowering Triglycerides in a Subject with Reduced Kidney Function and Diabetes Mellitus
EA202190547A1 (en)2018-08-172021-04-27Амарин Фармасьютикалз Айрлэнд Лимитед METHODS FOR REDUCING THE NEED FOR PERIPHERAL ARTERY REVASCULARIZATION IN A SUBJECT RECEIVING STATIN TREATMENT
RS65750B1 (en)2018-09-242024-08-30Amarin Pharmaceuticals Ie LtdMethods of reducing the risk of cardiovascular events in a subject
CA3113177A1 (en)2018-09-262020-04-02Amarin Pharmaceuticals Ireland LimitedCompositions and methods for treating or preventing diseases and/or disorders caused by exposure to air pollution
CA3126718A1 (en)2019-02-152020-08-20Amarin Pharmaceuticals Ireland LimitedMethods of reducing the risk of a cardiovascular event in a statin-treated subject by increasing serum and plasma epa and dpa levels
JP2021015274A (en)2019-07-122021-02-12キヤノン株式会社Electrochromic element, optical device, light control window, and image capturing device
CN114980973A (en)2019-11-122022-08-30阿马里纳药物爱尔兰有限公司Method for reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US20080057115A1 (en)*2004-06-112008-03-06Ono Pharmaceutical Co., Ltd.Capsule Stable Against Mastication
US20070212411A1 (en)*2006-03-092007-09-13Abdel FawzyCoating capsules with active pharmaceutical ingredients
US20100278879A1 (en)*2009-04-292010-11-04Amarin Pharma, Inc.Stable pharmaceutical composition and methods of using same
US20110218243A1 (en)*2010-03-042011-09-08Amarin Pharma, Inc.Compositions and methods for treating and/or preventing cardiovascular disease
WO2012128587A2 (en)*2011-03-232012-09-27Hanmi Pharm. Co., Ltd.Oral complex composition comprising omega-3 fatty acid ester and hmg-coa reductase inhibitor

Cited By (97)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US10314803B2 (en)2008-09-022019-06-11Amarin Pharmaceuticals Ireland LimitedPharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
US9855237B2 (en)2009-04-292018-01-02Amarin Pharmaceuticals Ireland LimitedMethods of treating mixed dyslipidemia
US10888537B2 (en)2009-04-292021-01-12Amarin Pharmaceuticals Ireland LimitedPharmaceutical compositions comprising omega-3 fatty acids
US11147787B2 (en)2009-04-292021-10-19Amarin Pharmaceuticals Ireland LimitedStable pharmaceutical composition and methods of using same
US11154526B2 (en)2009-04-292021-10-26Amarin Pharmaceuticals Ireland LimitedMethods of treating mixed dyslipidemia
US11103477B2 (en)2009-04-292021-08-31Amarin Pharmaceuticals Ireland LimitedStable pharmaceutical composition and methods of using same
US11033523B2 (en)2009-04-292021-06-15Amarin Pharmaceuticals Ireland LimitedPharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same
US10881632B2 (en)2009-04-292021-01-05Amarin Pharmaceuticals Ireland LimitedStable pharmaceutical composition and methods of using same
US10987331B2 (en)2009-04-292021-04-27Amarin Pharmaceuticals Ireland LimitedMethods of treating mixed dyslipidemia
US10940131B2 (en)2009-04-292021-03-09Amarin Pharmaceuticals Ireland LimitedMethods of treating mixed dyslipidemia
US10449172B2 (en)2009-04-292019-10-22Amarin Pharmaceuticals Ireland LimitedStable pharmaceutical composition and methods of using same
US9585856B2 (en)2009-04-292017-03-07Amarin Pharmaceuticals Ireland LimitedStable pharmaceutical composition and methods of using same
US11213504B2 (en)2009-04-292022-01-04Amarin Pharmaceuticals Ireland LimitedStable pharmaceutical composition and methods of using same
US11400069B2 (en)2009-04-292022-08-02Amarin Pharmaceuticals Ireland LimitedMethods of treating mixed dyslipidemia
US10842766B2 (en)2009-04-292020-11-24Amarin Pharmaceuticals Ireland LimitedStable pharmaceutical composition and methods of using same
US10792267B2 (en)2009-04-292020-10-06Amarin Pharmaceuticals Ireland LimitedMethods of treating mixed dyslipidemia
US10010517B2 (en)2009-04-292018-07-03Amarin Pharmaceuticals Ireland LimitedStable pharmaceutical composition and methods of using same
US11690820B2 (en)2009-04-292023-07-04Amarin Pharmaceuticals Ireland LimitedMethods of treating mixed dyslipidemia
US10265287B2 (en)2009-04-292019-04-23Amarin Pharmaceuticals Ireland LimitedMethods of reducing triglycerides and LDL-C
US10624870B2 (en)2009-04-292020-04-21Amarin Pharmaceuticals Ireland LimitedMethods of treating mixed dyslipidemia
US10220013B2 (en)2009-04-292019-03-05Amarin Pharmaceuticals Ireland LimitedMethods of treating mixed dyslipidemia
US12171738B2 (en)2009-06-152024-12-24Amarin Pharmaceuticals Ireland LimitedCompositions and methods for lowering triglycerides
US11464757B2 (en)2009-06-152022-10-11Amarin Pharmaceuticals Ireland LimitedCompositions and methods for lowering triglycerides
US11439618B2 (en)2009-06-152022-09-13Amarin Pharmaceuticals Ireland LimitedCompositions and methods for lowering triglycerides
US10842768B2 (en)2009-06-152020-11-24Amarin Pharmaceuticals Ireland LimitedCompositions and methods for lowering triglycerides
US10493058B2 (en)2009-09-232019-12-03Amarin Pharmaceuticals Ireland LimitedPharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
US11007173B2 (en)2009-09-232021-05-18Amarin Pharmaceuticals Ireland LimitedPharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
US11712428B2 (en)2010-11-292023-08-01Amarin Pharmaceuticals Ireland LimitedLow eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en)2010-11-292023-08-01Amarin Pharmaceuticals Ireland LimitedLow eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US10537544B2 (en)2011-11-072020-01-21Amarin Pharmaceuticals Ireland LimitedMethods of treating hypertriglyceridemia
US11291643B2 (en)2011-11-072022-04-05Amarin Pharmaceuticals Ireland LimitedMethods of treating hypertriglyceridemia
US10632094B2 (en)2011-11-072020-04-28Amarin Pharmaceuticals Ireland LimitedMethods of treating hypertriglyceridemia
US10973796B2 (en)2012-01-062021-04-13Amarin Pharmaceuticals Ireland LimitedCompositions and methods for lowering levels of high-sensitivity C-reactive protein (hs-CRP) in a subject
US9827219B2 (en)2012-01-062017-11-28Amarin Pharmaceuticals Ireland LimitedCompositions and methods for lowering levels of high-sensitivity C-reactive protein (HS-CRP) in a subject
US9918954B2 (en)2012-06-292018-03-20Amarin Pharmaceuticals Ireland LimitedMethods of reducing the risk of a cardiovascular event in a subject on statin therapy
US10383840B2 (en)2012-06-292019-08-20Amarin Pharmaceuticals Ireland LimitedMethods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease
US9603826B2 (en)2012-06-292017-03-28Amarin Pharmaceuticals Ireland LimitedMethods of reducing the risk of a cardiovascular event in a subject on statin therapy
US9610272B2 (en)2012-06-292017-04-04Amarin Pharmaceuticals Ireland LimitedMethods of reducing the risk of a cardiovascular event in a subject on statin therapy
US10555925B1 (en)2012-06-292020-02-11Amarin Pharmaceuticals Ireland LimitedMethods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease
US10555924B2 (en)2012-06-292020-02-11Amarin Pharmaceuticals Ireland LimitedMethods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease
US9623001B2 (en)2012-06-292017-04-18Amarin Pharmaceuticals Ireland LimitedMethods of reducing the risk of a cardiovascular event in a subject on statin therapy
US10568861B1 (en)2012-06-292020-02-25Amarin Pharmaceuticals Ireland LimitedMethods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease
US10576054B1 (en)2012-06-292020-03-03Amarin Pharmaceuticals Ireland LimitedMethods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease
US10278938B2 (en)2012-06-292019-05-07Amarin Pharmaceuticals Ireland LimitedMethods of reducing the risk of a cardiovascular event in a subject on statin therapy
US9693984B2 (en)2012-06-292017-07-04Amarin Pharmaceuticals Ireland LimitedMethods of reducing the risk of a cardiovascular event in a subject on statin therapy
US10278937B2 (en)2012-06-292019-05-07Amarin Pharmaceuticals Ireland LimitedMethods of reducing the risk of a cardiovascular event in a subject on statin therapy
US9693985B2 (en)2012-06-292017-07-04Amarin Pharmaceuticals Ireland LimitedMethods of reducing the risk of a cardiovascular event in a subject on statin therapy
US10278939B2 (en)2012-06-292019-05-07Amarin Pharmaceuticals Ireland LimitedMethods of reducing the risk of a cardiovascular event in a subject on statin therapy
US9693986B2 (en)2012-06-292017-07-04Amarin Pharmaceuticals Ireland LimitedMethods of reducing the risk of a cardiovascular event in a subject on statin therapy
US10016386B2 (en)2012-06-292018-07-10Amarin Pharmaceuticals Ireland LimitedMethods of reducing the risk of a cardiovascular event in a subject on statin therapy
US10278936B2 (en)2012-06-292019-05-07Amarin Pharmaceuticals Ireland LimitedMethods of reducing the risk of a cardiovascular event in a subject on statin therapy
US10792270B2 (en)2012-06-292020-10-06Amarin Pharmaceuticals Ireland LimitedMethods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease
US10278935B2 (en)2012-06-292019-05-07Amarin Pharmaceuticals Ireland LimitedMethods of reducing the risk of a cardiovascular event in a subject on statin therapy
US9918955B2 (en)2012-06-292018-03-20Amarin Pharmaceuticals Ireland LimitedMethods of reducing the risk of a cardiovascular event in a subject on statin therapy
US10894028B2 (en)2012-06-292021-01-19Amarin Pharmaceuticals Ireland LimitedMethods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease
US11229618B2 (en)2012-11-062022-01-25Amarin Pharmaceuticals Ireland LimitedCompositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US11179362B2 (en)2012-11-062021-11-23Amarin Pharmaceuticals Ireland LimitedCompositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US11141399B2 (en)2012-12-312021-10-12Amarin Pharmaceuticals Ireland LimitedMethods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en)2012-12-312017-11-14A,arin Pharmaceuticals Ireland LimitedCompositions comprising EPA and obeticholic acid and methods of use thereof
US10166209B2 (en)2013-02-062019-01-01Amarin Pharmaceuticals Ireland LimitedMethods of reducing apolipoprotein C-III
US10265290B2 (en)2013-02-062019-04-23Amarin Pharmaceuticals Ireland LimitedMethods of reducing apolipoprotein C-III
US11185525B2 (en)2013-02-062021-11-30Amarin Pharmaceuticals Ireland LimitedMethods of reducing apolipoprotein C-III
US10610508B2 (en)2013-02-062020-04-07Amarin Pharmaceuticals Ireland LimitedMethods of reducing apolipoprotein C-III
US10973797B2 (en)2013-02-062021-04-13Amarin Pharmaceuticals Ireland LimitedMethods of reducing apolipoprotein c-III
US10675263B2 (en)2013-02-062020-06-09Amarin Pharmaceuticals Ireland LimitedMethods of reducing apolipoprotein C-III
US9624492B2 (en)2013-02-132017-04-18Amarin Pharmaceuticals Ireland LimitedCompositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US10167467B2 (en)2013-02-132019-01-01Amarin Pharmaceuticals Ireland LimitedCompositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US10851374B2 (en)2013-02-132020-12-01Amarin Pharmaceuticals Ireland LimitedCompositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9855240B2 (en)2013-02-192018-01-02Amarin Pharmaceuticals Ireland LimitedCompositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US10206898B2 (en)2013-03-142019-02-19Amarin Pharmaceuticals Ireland LimitedCompositions and methods for treating or preventing obesity in a subject in need thereof
US9283201B2 (en)2013-03-142016-03-15Amarin Pharmaceuticals Ireland LimitedCompositions and methods for treating or preventing obesity in a subject in need thereof
US11547710B2 (en)2013-03-152023-01-10Amarin Pharmaceuticals Ireland LimitedPharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en)2013-06-062021-04-06Amarin Pharmaceuticals Ireland LimitedCo-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US10888539B2 (en)2013-09-042021-01-12Amarin Pharmaceuticals Ireland LimitedMethods of treating or preventing prostate cancer
US10722485B2 (en)2013-10-102020-07-28Amarin Pharmaceuticals Ireland LimitedCompositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US9585859B2 (en)2013-10-102017-03-07Amarin Pharmaceuticals Ireland LimitedCompositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10292959B2 (en)2013-10-102019-05-21Amarin Pharmaceuticals Ireland LimitedCompositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US11285127B2 (en)2013-10-102022-03-29Amarin Pharmaceuticals Ireland LimitedCompositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US11052063B2 (en)2014-06-112021-07-06Amarin Pharmaceuticals Ireland LimitedMethods of reducing RLP-C
US10561631B2 (en)2014-06-112020-02-18Amarin Pharmaceuticals Ireland LimitedMethods of reducing RLP-C
US11446269B2 (en)2014-06-162022-09-20Amarin Pharmaceuticals Ireland LimitedMethods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10172818B2 (en)2014-06-162019-01-08Amarin Pharmaceuticals Ireland LimitedMethods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
EP3412280A4 (en)*2016-02-052019-08-28Korea United Pharm. Inc.Oral composite formulation comprising fat-soluble drug and solid preparation coated with oil repellent base
US10842765B2 (en)2016-03-152020-11-24Amarin Pharmaceuticals Ireland LimitedMethods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US10406130B2 (en)2016-03-152019-09-10Amarin Pharmaceuticals Ireland LimitedMethods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10966951B2 (en)2017-05-192021-04-06Amarin Pharmaceuticals Ireland LimitedCompositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en)2018-03-022021-07-13Amarin Pharmaceuticals Ireland LimitedCompositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
US10668042B2 (en)2018-09-242020-06-02Amarin Pharmaceuticals Ireland LimitedMethods of reducing the risk of cardiovascular events in a subject
US10786478B2 (en)2018-09-242020-09-29Amarin Pharmaceuticals Ireland LimitedMethods of reducing the risk of cardiovascular events in a subject
US11369582B2 (en)2018-09-242022-06-28Amarin Pharmaceuticals Ireland LimitedMethods of reducing the risk of cardiovascular events in a subject
US11298333B1 (en)2018-09-242022-04-12Amarin Pharmaceuticals Ireland LimitedMethods of reducing the risk of cardiovascular events in a subject
US11116742B2 (en)2018-09-242021-09-14Amarin Pharmaceuticals Ireland LimitedMethods of reducing the risk of cardiovascular events in a subject
US11000499B2 (en)2018-09-242021-05-11Amarin Pharmaceuticals Ireland LimitedMethods of reducing the risk of cardiovascular events in a subject
US11717504B2 (en)2018-09-242023-08-08Amarin Pharmaceuticals Ireland LimitedMethods of reducing the risk of cardiovascular events in a subject
US11116743B2 (en)2018-09-242021-09-14Amarin Pharmaceuticals Ireland LimitedMethods of reducing the risk of cardiovascular events in a subject
US12246003B2 (en)2018-09-242025-03-11Amarin Pharmaceuticals Ireland LimitedMethods of reducing the risk of cardiovascular events in a subject
US11986452B2 (en)2021-04-212024-05-21Amarin Pharmaceuticals Ireland LimitedMethods of reducing the risk of heart failure

Also Published As

Publication numberPublication date
US20190099422A1 (en)2019-04-04
US11547710B2 (en)2023-01-10
US20240016803A1 (en)2024-01-18

Similar Documents

PublicationPublication DateTitle
US20240016803A1 (en)Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US20240148683A1 (en)Stable pharmaceutical composition and methods of using same
US10851374B2 (en)Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US20140221358A1 (en)Compositions comprising eicosapentaenoic acid and diazoxide and methods of use thereof
US20140271907A1 (en)Compositions comprising eicosapentaenoic acid and krill oil and methods of use thereof
AU2014203034B2 (en)Stable pharmaceutical composition and methods of using same
AU2018202792B2 (en)Stable pharmaceutical composition and methods of using same

Legal Events

DateCodeTitleDescription
ASAssignment

Owner name:CPPIB CREDIT EUROPE S.A R.L., LUXEMBOURG

Free format text:SECURITY INTEREST;ASSIGNOR:AMARIN PHARMACEUTICALS IRELAND LIMITED;REEL/FRAME:044938/0257

Effective date:20171220

STCBInformation on status: application discontinuation

Free format text:ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

ASAssignment

Owner name:AMARIN PHARMACEUTICALS IRELAND LIMITED, IRELAND

Free format text:RELEASE BY SECURED PARTY;ASSIGNOR:CPPIB CREDIT EUROPE S.A R.L.;REEL/FRAME:054484/0552

Effective date:20201119

ASAssignment

Owner name:AMARIN PHARMACEUTICALS IRELAND LIMITED, IRELAND

Free format text:ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GRANDOLFI, GEORGE;REEL/FRAME:057105/0803

Effective date:20210719


[8]ページ先頭

©2009-2025 Movatter.jp